Applied Clinical Trials
A comprehensive listing of U.S. departments and offices that includes the telephone numbers of directors, commissioners, and advisors.
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Director
Jerry Menikoff (240) 453-6900
NIH Institutes, Center, and Divisions
Deputy Director and Director, Office of International Activities
Melody Lin (240) 453-8126
Associate Director, Regulatory Affairs
Michael Carome (240) 453-8237
Director, Division of Compliance Oversight
Kristina Borror (240) 453-8132
Director, Division of Education and Development
Elyse Summers* (240) 453-8236
Director,Division of Policy and Assurances
Irene Stith-Coleman (240) 453-8138
FOOD AND DRUG ADMINISTRATION
Commissioner
Andrew von Eschenbach (301) 827-3310
Principal Deputy Commissioner and Chief Scientist
Frank Torti (301) 827-3310
Chief of Staff
Susan Winckler (301) 827-0087
Deputy Commissioner for Operations and Chief Operating Officer
John Dyer (301) 827-1166
Deputy Commissioner for Policy, Planning, and Preparedness
Randall Lutter (301) 827-3370
Deputy Commissioner for International and Special Programs
Murray Lumpkin (301) 827-5709
Chief Counsel
Gerald Masoudi (301) 827-1137
Assistant Commissioner for External Relations
Larry Bachorik* (301) 827-1352
Assistant Commissioner for Policy and Planning
Jeffrey Shuren (301) 827-3360
Assistant Commissioner for Planning
Malcolm Bertoni (301) 827-5292
Assistant Commissioner for Counterterrorism and Emerging Threats
Boris Lushniak (301) 827-4067
DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION
Assistant Commisioner for Integrity and Accountability
William McConagha (301) 827-4427
Associate Commissioner for International Programs
Melinda Plaisier (301) 827-4480
Director, Office of Pediatric Therapeutics
Dianne Murphy (301) 827-1996
Director, Office of Combination Products
Thinh Nguyen (301) 427-1934
Associate Commissioner for Management
Kathleen Heuer (301) 255-6762
Associate Commissioner for Critical Path Programs
Rachel Behrman (301) 827-1512
Director, National Center for Toxicological Research
William Slikker (870) 543-7203
Associate Commissioner for Science and Health Coordination
Norris Alderson (301) 827-3340
Assistant Commissioner for Women's Health
Kathleen Uhl (301) 827-0350
Director, Office of Orphan Products Development
Timothy Cote (301) 827-3666
GoodClinicalPracticeProgram
Director
Joanne Less (301) 827-3340
Special Assistant to the Director
Patricia Beers Block (301) 827-3340
Senior Bioethicist
Sara Goldkind (301) 827-3340
Expert Consumer Safety Officer
Carolyn Hommel (301) 827-3340
Senior Advisor for Clinical Science
David Lepay (301) 827-3340
Policy Analyst
Marsha Melvin (301) 827-3340
Senior Health Policy Analyst
Kathleen Pfaender (301) 827-3340
Biophysicist
Jean Toth-Allen (301) 827-3340
Associate Commissioner for Regulatory Affairs
Michael Chappell (301) 827-3107
Associate Deputy Commissioner for Compliance Policy
Steven Solomon (301) 827-3101
Director
Daniel Schultz (240) 276-3939
Director, Office of Device Evaluation
Donna Bea Tillman (240) 276-3993
Director, Office of Compliance
Timothy Ulatowski (301) 276-0100
Director, Division of Bioresearch Monitoring
Michael Marcarelli (301) 276-0125
Director, Office of In Vitro Diagnostic Device Evaluation and Safety
Steven Gutman (240) 276-0375
Director, Office of Surveillance and Biometrics
Susan Gardner (240) 276-3351
Director
Janet Woodcock (301) 796-5400
Deputy Director
Douglas Throckmorton (301) 796-5400
Associate Director for Medical Informatics
Randy Levin (301) 827-7784
Associate Director for Planning and Business Informatics
Theresa Mullin (301) 796-5400
Associate Director for International Programs
Justina Molzon (301) 796-5400
Associate Director for Safety Policy and Communications
Paul Seligman (301) 796-5401
Associate Director for Regulatory Policy
Jane Axelrad (301) 796-5400
Director, Office of Executive Programs
Deborah Henderson (301) 796-3200
Director, Office of Management
Russell Abbott (301) 796-3300
Director, Office of Training and Communication
Nancy Smith (301) 796-3700
Director, Office of Information Technology
James Shugars (301) 827-6240
Director, Office of Counterterrorism and Emergency Coordination
Rosemary Roberts (301) 796-2210
Director
ShaAvhree Buckman (301) 796-2600
Director, Office of Clinical Pharmacology
Lawrence Lesko (301) 796-1656
Director, Office of Biostatistics
Robert O'Neill (301) 796-1700
Director
Deborah Autor (301) 796-3100
Deputy Director
Joe Famulare (301) 796-3100
Director, Division of Scientific Investigations
Leslie Ball (301) 796-3150
Deputy Director
Joseph Salewski (301) 796-3395
Chief, Good Clinical Practices Branch I
Constance Lewin (301) 796-3397
Chief, Good Clinical Practices Branch II
Tejashri Purohit-Sheth (301) 796-3402
Chief, GLP/Bioequivalence Branch
C.T. Viswanathan (301) 796-3394
Director
Robert Temple (301) 796-2270
Deputy Director
Rachel Behrman* (301) 796-2270
Director, Division of Drug Marketing, Advertising, and Communications
Thomas Abrams (301) 796-1200
Director
John Jenkins (301) 796-0700
Deputy Director
Sandra Kweder (301) 796-0700
Director, Office of Drug Evaluation I
Robert Temple* (301) 796-2270
Director, Office of Drug Evaluation II
Curtis Rosebraugh (301) 796-2310
Director, Office of Drug Evaluation III
Julie Beitz (301) 796-2100
Director, Office of Antimicrobial Products
Edward M. Cox (301) 796-1300
Director, Office of Oncology Products
Richard Pazdur (301) 796-2340
Director, Office of Nonprescription Products
Charles Ganley (301) 796-2060
Director
Helen Winkle (301) 796-2400
Deputy Director
Keith Webber (301) 796-2400
Director, Office of New Drug Quality Assessment
Moheb Nasr (301) 796-1900
Director, Office of Generic Drugs
Gary Buehler (240) 276-9310
Director, Office of Testing and Research
Vincent Vilker (301) 796-0200
Director, Office of Biotechnology Products
Steven Kozlowski (301) 796-2390
Director
Gerald Dal Pan (301) 796-2380
Deputy Director
Henry "Skip" Francis (301) 796-2380
Director, Division of Risk Management
Claudia Karwoski* (301) 796-9832
Director, Division of Epidemiology
Solomon Iyasu (301) 796-2370
Director, Division of Medication Error Prevention and Analysis
Carol Holquist (301) 796-2360
Director, Division of Pharmacovigilance I
Mark Avigan (301) 796-2350
Director, Division of Pharmacovigilance II
Ann McMahon* (301) 796-2350
Director
Jesse Goodman (301) 827-0372
Deputy Director
Karen Midthun (301) 827-0372
Associate Director for Research
Carolyn Wilson (301) 827-0377
Associate Director for Policy
Diane Maloney (301) 827-0372
Associate Director for Quality Assurance
Sheryl Lard-Whiteford (301) 827-0379
Associate Director for Review Management
Robert Yetter (301) 827-0373
Science Communications Advisor
Marc Kusinitz (301) 827-0372
Senior Advisor for International Affairs
Joan W. Blair (301) 827-0639
Senior Advisory for Counterterrorism/ Medical Countermeasures
Cynthia Kelley (301) 827-0636
Senior Advisor for Chemistry and Manufacturing Controls
Christopher Joneckis (301) 435-5681
Senior Regulatory Affairs Advisor
Lydia Falk (301) 827-9424
Director, Office of Biostatistics and Epidemiology
Robert Ball (301) 827-3034
Director, Office of Information Technology
Ginger Leo (301) 827-1368
Director, Office of Communication, Training, and Manufacturers Assistance
Lorrie McNeill (301) 827-2000
Director, Office of Management
James Sigg* (301) 827-1320
Director, Office of Blood Research and Review
Jay Epstein (301) 827-3518
Director, Office of Vaccines Research and Review
Norman Baylor (301) 827-0655
Director, Office of Cellular, Tissue, and Gene Therapies
Celia Witten (301) 827-6536
Director, Office of Compliance and Biologics Quality
Mary Anne Malarkey (301) 827-6190
Director, Division of Inspections and Surveillance
Gilliam Conley (301) 827-6220
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.
Citius Pharmaceuticals Resubmits BLA to FDA for Lymphir to Treat Cutaneous T-Cell Lymphoma
March 19th 2024Pivotal Phase III Study 302 trial data show an objective response rate of 36.2% based on an independent review committee assessment in the treatment of relapsed/refractory cutaneous T-cell lymphoma.